Monopar Therapeutics announced that the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients. Professor Hicks will enroll patients at the Melbourne Theranostic Innovation Centre and will use one of the world’s most sensitive clinical total-body PET/CT scanners, the Siemens Biograph Vision Quadra, to image the targeting ability of MNPR-101-Zr in cancer patients. Professor Rodney Hicks, MBBS, MD, FRACP, FICIS, FAAHMS is the Founder, Chief Medical Officer, and Board Chair of Precision Molecular Imaging & Theranostics Pty Ltd, the company that operates MTIC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MNPR:
- Monopar Therapeutics announces preclinical data for its MNPR-101 program
- Monopar Therapeutics’ Breakthrough in Advanced Cancer Treatment
- Monopar Therapeutics Advances with Phase 1 Trial Approval
- Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
- Monopar receives clearance to proceed with first-in-human trial of MNPR-101-Zr
